C
CASI
vs
S&P 500
S&P 500
Over the past 12 months, CASI has underperformed S&P 500, delivering a return of -70% compared to the S&P 500's +14% growth.
Stocks Performance
CASI vs S&P 500
Performance Gap
CASI vs S&P 500
Performance By Year
CASI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CASI Pharmaceuticals Inc
Glance View
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company is headquartered in Rockville, Maryland and currently employs 168 full-time employees. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States and throughout the world. The company is also focused on acquiring, developing, and commercializing products that augment its hematology-oncology therapeutic focus as well as other areas of unmet medical need. The Company’s operations in China are conducted primarily through its subsidiaries, which include CASI Pharmaceuticals (China) Co., Ltd. (CASI China), which is wholly owned and is located in Beijing, China, and CASI Pharmaceuticals (Wuxi) Co., Ltd. (CASI Wuxi), which is located in Wuxi, China. Its commercial product, EVOMELA, is developed for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in its pipeline include CNCT19, BI-1206, CB-5339 and CID-103.
